Physician

Anne M. Noonan, MD

According to 2025 Medicare claims, Anne Noonan, MD (NPI: 1477887479) practices medical oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is OSU INTERNAL MEDICINE, LLC (NPI: 1740231448; TIN: 311369596) and primary practice location at 43221-3502. Noonan is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Noonan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 123 traditional Medicare patients, billed 370 HCPCS/CPT codes, and received $37,158 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 373 prescription claims across 105 beneficiaries totaling $696,821 in drug costs, led by Creon (Lipase/Protease/Amylase). DME data shows 36 claims. Open Payments data shows 24 records totaling $114,761. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $41,027 and ending at $37,158. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $453,548 and ending at $696,821. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $17,749 to $708.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	137	515	$41,027
2016	269	735	$59,046
2017	276	771	$59,001
2018	241	587	$47,551
2019	188	536	$47,685
2020	129	396	$33,900
2021	130	496	$53,409
2022	133	387	$40,161
2023	120	364	$37,789
2024	123	370	$37,158

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	57	388	$453,548
2016	64	172	$179,712
2017	150	686	$482,036
2018	152	581	$134,728
2019	90	250	$106,552
2020	60	217	$359,378
2021	70	371	$347,269
2022	69	241	$409,466
2023	92	347	$594,722
2024	105	373	$696,821

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	34	278	$42,024
2016	N/R	60	$14,499
2017	23	89	$22,182
2018	N/R	44	$9,194
2019	11	174	$67,293
2020	N/R	49	$5,198
2021	N/R	61	$5,902
2022	N/R	N/R	N/R
2023	N/R	22	$5,317
2024	N/R	36	$1,155

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	34	34	$133
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	97	280	$104
99443	Telephone medical discussion with physician, 21-30 minutes	17	22	$73
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	16	17	$63

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Creon	Lipase/Protease/Amylase	22	747	$33,944
Prochlorperazine Maleate	Prochlorperazine Maleate	31	353	$385
Dexamethasone	Dexamethasone	23	313	$230
Olanzapine	Olanzapine	18	300	$178
Oxycodone Hcl	Oxycodone Hcl	14	195	$145

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$816
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$5,579	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	12	$109,182	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anne M. Noonan, MD?

Tedicare shows public-source Medicare data for Anne M. Noonan, MD (NPI 1477887479), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anne M. Noonan, MD have ACO affiliation data?

Anne M. Noonan, MD is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Anne M. Noonan, MD?

Anne M. Noonan, MD is linked to OSU INTERNAL MEDICINE, LLC (billing NPI 1740231448) in the available physician profile data.

Does Anne M. Noonan, MD have Open Payments data?

Anne M. Noonan, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.